Received: 10 January 2023
Accepted: 16 May 2023
First Online: 13 June 2023
: JB performed consultancy work for BMS, Janssen, Astellas, Merck and Pfizer of which all financial rewards were attributed to the Erasmus Medical Center. In addition, JB was involved in research agreements for MSD and Janssen. TZ has been employed on project basis for Janssen Pharmaceuticals. The remaining authors have no competing interests to declare.
: The study has been approved by the Medical Ethical Committee of the Erasmus University Medical Centre (MEC 2022 − 0257) on 10/10/2022 and has been registered at Clinicaltrials.gov (NCT05600127) on 31/10/2022. The study will be conducted according to the principles of the Declaration of Helsinki (10th version, Portaleza, 2013) and will be in accordance with the Dutch Medical Research Involving Human Subjects Act (WMO). Informed consent to participate in the study is obtained from all participants. Individual patient data will not be published.
: Not applicable.